FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Cancer Année : 2022

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study.

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (3) , (8) , , (9, 10) , (11) , , , , (12) , (13) , , (3) , (14, 15) , (7, 16) , (17, 18) , (19) , (20, 21, 22) , (23) , (24) , (25) , , , (26) , (27) , (28) , (29) , (30) , (31, 16) , (17, 18, 32) , (33) , (34, 35, 26) , (35)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Morgane Stouvenot
  • Fonction : Auteur
Tiffany Darbas
  • Fonction : Auteur
Benjamin Auberger
  • Fonction : Auteur
Tiphaine Godet
  • Fonction : Auteur
Marion Jaffrelot
  • Fonction : Auteur
Cassandre Gluszak
  • Fonction : Auteur
Pauline Gignoux
  • Fonction : Auteur
Stéphanie Trager
  • Fonction : Auteur

Résumé

After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR\,+\,PR\,+\,SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2\,years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2~months, median OS was 13.0~months (95% CI: 11.3-14.7) and 10.4~months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P\,<\,.0001). Median PFS was 6.0~months (95% CI: 5.4-6.5) and 5.1~months (95% CI: 4.3-5.6) (P\,<\,.0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P~=~.0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.
Fichier non déposé

Dates et versions

hal-03735625 , version 1 (21-07-2022)

Identifiants

Citer

Cécile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, et al.. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study.. International Journal of Cancer, 2022, ⟨10.1002/ijc.34166⟩. ⟨hal-03735625⟩
35 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More